/
/
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Se requiere una suscripción a JoVE para ver este contenido. Inicie sesión o comience su prueba gratuita.
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
12,302 Views
•
11:34 min
•
December 05, 2017
DOI:
1Division of Pathology,Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 2School of Medicine,University of Milan, 3School of Biology,University of Pavia, 4Division of Breast Surgery,Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, 5Division of Medical Oncology,Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, 6Department of Biomedical, Surgical, and Dental Sciences,University of Milan
Summary
Automatically generated
Heterogeneous distribution of HER2-positive cells can be observed in a subset of breast cancers and generates clinical dilemmas. Here, we introduce a reliable and cost-effective protocol to define, quantify, and compare HER2 intra-tumor genetic heterogeneity in a large series of heterogeneously processed breast cancers.
Read Article
Cite this Article
Ercoli, G., Lopez, G., Ciapponi, C., Corti, C., Despini, L., Gambini, D., Runza, L., Blundo, C., Sciarra, A., Fusco, N. Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers. J. Vis. Exp. (130), e56686, doi:10.3791/56686 (2017).
Copy